Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
1.545
-0.037 (-2.34%)
Oct 8, 2025, 11:37 AM EDT - Market open
Barinthus Biotherapeutics Employees
Barinthus Biotherapeutics had 105 employees as of December 31, 2024. The number of employees decreased by 25 or -19.23% compared to the previous year.
Employees
105
Change (1Y)
-25
Growth (1Y)
-19.23%
Revenue / Employee
$142,562
Profits / Employee
-$661,200
Market Cap
62.91M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 105 | -25 | -19.23% |
Dec 31, 2023 | 130 | 23 | 21.50% |
Dec 31, 2022 | 107 | 35 | 48.61% |
Dec 31, 2021 | 72 | 24 | 50.00% |
Dec 31, 2020 | 48 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BRNS News
- 4 days ago - BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS - Business Wire
- 8 days ago - Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases - GlobeNewsWire
- 4 months ago - Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025 - Accesswire
- 7 months ago - Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments - GlobeNewsWire
- 7 months ago - Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11 - Accesswire
- 9 months ago - Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update - GlobeNewsWire
- 11 months ago - Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer - GlobeNewsWire
- 11 months ago - Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion - GlobeNewsWire